EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study

Guanhong Luo, Jinping Xu, Guanjie Qin, Yixin Su, Yufei Pan, Jianxun Lu, Yueyun Xie, Bin Zhang, Jinxuan Dai, Xiangyun Kong, Yuan Xie, Xiaolan Ruan und 3 weitere

Cancer Control · 2025

DOI: 10.1177/10732748251385282 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Control, 2025. Verfasst von Guanhong Luo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, CSCO Youth Innovative Oncology Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Platinum-based chemotherapy is important for the treatment for recurrent or metastatic nasopharyngeal carcinomas (RM-NPCs), as recommended by current clinical guidelines. However, the prognosis of RM-NPC patients remains poor. This study aimed to evaluate the efficacy and safety of vascular-targeting agents apatinib or anlotinib plus chemotherapy for RM-NPC treatment.

Methods

This retrospective multicenter study, conducted at 4 hospitals in Guangxi Province, China, between January 2017 and December 2021, included 198 patients. Propensity score matching (PSM) was used to minimize potential selection bias between groups. After PSM, a total of 150 patients were included in the study. Chemotherapy was administered with and without vascular-targeting agents in 58 and 92 patients, respectively. The primary endpoint was progression-free survival (PFS), assessed by a blinded independent review committee according to RECIST v.1.1. The secondary end points were overall survival (OS) and safety.

Results

After PSM, median PFS was significantly higher in the combination group (8.0 months [95% CI, 5.7-8.3 months]) than in the chemotherapy alone group (5.0 months [95% CI, 4.1-5.9 months], P = 0.014), with a hazard ratio of 0.65 (95% CI, 0.46-0.92). The combination group exhibited a higher median OS compared to the chemotherapy alone group (45 months [95% CI, 21.3-52.7] vs 18 months [95% CI, 13.0-27.0 months], P = 0.019), representing a hazard ratio of 0.58 (95% CI, 0.37-0.92). In the combination therapy group, the most common adverse event was hand-foot syndrome (n = 16/58 [27.6%]).

Conclusion

The addition of vascular-targeting agents to chemotherapy for RM-NPC patients provided superior efficacy compared to chemotherapy alone, along with a manageable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalPyridinesAdultAgedFemaleHumansMaleMiddle AgedChinaIndolesProgression-Free SurvivalQuinolinesRetrospective Studies

Stichwörter der Autor:innen

anlotinibapatinibefficacynasopharyngeal carcinomatargeted therapy plus chemotherapyvascular targeting agents

Substanzen

anlotinibapatinibIndolesPyridinesQuinolines

Autor:innen und Institutionen

  • Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.
  • Key Laboratory of Oncology (Guilin Medical University), Education Department of Guangxi Zhuang Autonomous Region, Guilin, China.
  • Department of Radiation Oncology, Lingshan People's Hospital, Lingshan, China.
  • Department of Radiation Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
  • Department of Oncology, Nanning First People's Hospital, Naning, China.
  • Department of Oncology, The 924th Hospital of the Chinese people's Liberation Army, Guilin, China.

ORCID-Profile: Wei Jiang

Förderung

  • National Natural Science Foundation of China
  • CSCO Youth Innovative Oncology Research Fund

Zitieren

APA

Luo, G., Xu, J., Qin, G., Su, Y., Pan, Y., Lu, J., Xie, Y., Zhang, B., Dai, J., Kong, X., Xie, Y., Ruan, X., Mo, Y., Zhang, R., & Jiang, W. (2025). Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study. Cancer Control. https://doi.org/10.1177/10732748251385282

Vancouver

Luo G, Xu J, Qin G, Su Y, Pan Y, Lu J, et al. Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study. Cancer Control. 2025. doi:10.1177/10732748251385282

BibTeX
@article{Luo2025,
  author = {Luo, Guanhong and Xu, Jinping and Qin, Guanjie and Su, Yixin and Pan, Yufei and Lu, Jianxun and Xie, Yueyun and Zhang, Bin and Dai, Jinxuan and Kong, Xiangyun and Xie, Yuan and Ruan, Xiaolan and Mo, Yunyan and Zhang, Ruyun and Jiang, Wei},
  title = {Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study},
  journal = {Cancer Control},
  year = {2025},
  doi = {10.1177/10732748251385282}
}
Kostenlos starten →